Drug class
Immunologic Factors clinical trials
A class of medicines: the studies that test any of its 36 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the immunologic factors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Tocladesine
- 2
- Antibodies, Bispecific
- 2
- Diphtheria Antitoxin
- 1
- Pidotimod
- 1
- Antivenins
- 1
- Immunoglobulin Fab Fragments
- 1
- Lexatumumab
- 1
- Beta-1,3-glucan
- 1
- Complement C1s
- 1
Studies by the year they started
3,261 studies that test it; most in 2009 (175); 2 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 2 |
| 1991 | 1 |
| 1992 | 3 |
| 1993 | 4 |
| 1994 | 3 |
| 1995 | 15 |
| 1996 | 9 |
| 1997 | 17 |
| 1998 | 26 |
| 1999 | 33 |
| 2000 | 42 |
| 2001 | 44 |
| 2002 | 81 |
| 2003 | 102 |
| 2004 | 136 |
| 2005 | 146 |
| 2006 | 169 |
| 2007 | 151 |
| 2008 | 171 |
| 2009 | 175 |
| 2010 | 157 |
| 2011 | 154 |
| 2012 | 151 |
| 2013 | 118 |
| 2014 | 114 |
| 2015 | 123 |
| 2016 | 119 |
| 2017 | 100 |
| 2018 | 89 |
| 2019 | 112 |
| 2020 | 126 |
| 2021 | 98 |
| 2022 | 105 |
| 2023 | 99 |
| 2024 | 77 |
| 2025 | 100 |
| 2026 | 89 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 241
Who runs them
Industry 779 · Other 2,513
M.D. Anderson Cancer Center (146) · National Cancer Institute (NCI) (144) · Hoffmann-La Roche (103) · Celgene (71) · Mayo Clinic (62) · Memorial Sloan Kettering Cancer Center (52) · Biogen (50) · Genentech, Inc. (44)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 3,292
- Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2Enrolling by invitationPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT05350774Written as IV immunoglobulin
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07830485Written as Lenalidomide
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT06015880Written as Lenalidomide
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT05861050Written as Lenalidomide
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaRecruitingPhase 3National Cancer Institute (NCI)NCT06337318Written as Rituximab
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingPhase 1/2BeOne MedicinesNCT04973605Written as Pomalidomide
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingPhase 1/2Wake Forest University Health SciencesNCT04822337Written as Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
- Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingPhase 2National Cancer Institute (NCI)NCT01419561Written as Rituximab
- Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyRecruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00977977Written as Rituximab Infusion
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingPhase 3BeOne MedicinesNCT06943872Written as Rituximab
- A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular InflammationRecruitingPhase 2BiogenNCT07219043Written as Felzartamab
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT07892027Written as Natalizumab
- A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person SyndromeNot yet recruitingPhase 3Kedrion S.p.A.NCT07552987Written as Kedrion IVIg 10%
- A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)Not yet recruitingPhase 2BiogenNCT07889362Written as Felzartamab
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingPhase 1K36 Therapeutics, Inc.NCT05651932Written as Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
- The HIt HArd and hiT Early in Multiple Sclerosis TrialRecruitingPhase 2Uppsala UniversityNCT07517185Written as Sequential treatment with rituximab and cladribine
- Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT07578077Written as Rituximab
- A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years OldRecruitingPhase 2BiogenNCT07722546Written as Felzartamab
- A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)RecruitingPhase 3Kedrion S.p.A.NCT07059000Written as Kedrion IVIG 10%
- Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBTNot yet recruitingPhase 2Anhui Provincial HospitalNCT07885982Written as Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
See all 3,292 studies that test one of the immunologic factors →